These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Metachronous resection of metastatic lymph nodes in patients with hepatocellular carcinoma.
    Author: Hashimoto M, Matsuda M, Watanabe G.
    Journal: Hepatogastroenterology; 2009; 56(91-92):788-92. PubMed ID: 19621703.
    Abstract:
    BACKGROUND/AIMS: Lymph node metastases are common at autopsy; being found in 28% of autopsy cases of hepatocellular carcinoma have lymph nodes metastases. However, effective treatment for metastatic lymph nodes has not yet been established. METHODOLOGY: We resected lymph node metastases in 8 out of 10 hepatocellular carcinoma patients. We assessed the clinical course and the prognosis of these patients to determine the effectiveness of resecting metastatic lymph nodes and the factors related to survival. RESULTS: Eight out of 10 patients underwent lymph node resection nine times, while removal of metastatic lymph nodes proved impossible in two patients. The 1-year survival rate was 89% in resected cases. Two patients survived for more than 2 years without recurrence or with controlled recurrence of their cancer. The two unresectable patients had a poor prognosis, with the largest survival time being 11 months. CONCLUSIONS: Surgical resection is an option for selected patients with lymph node metastases of hepatocellular carcinoma and the complete removal of metastatic lymph nodes may achieve a survival benefit in selected patients. Metachronous lymph node metastases should be resected in patients with a controlled primary liver tumor, because no other treatment option for lymph nodes metastases has yet been established.
    [Abstract] [Full Text] [Related] [New Search]